US equities |
SPCX $166.42 ▲+4.69% NVDA $236.82 ▲+1.23% MU $1,064.42 ▼-0.97% TSLA $377.68 ▲+1.91% MSFT $526.13 ▲+1.66% SNDK $1,712.14 ▼-0.46% INTC $117.25 ▼-1.74% META $745.26 ▲+2.36%
FinancialContent

Dyadic International, Inc. - Common Stock (NQ:DYAI)

0.4600 +0.0042 (+0.92%)
Delayed Quote Updated: 11:45 AM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Dyadic International, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Dyadic to Present at Industry Events in November
From Dyadic International, Inc.
Via GlobeNewswire
News headline image
Dyadic to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
From Dyadic International, Inc.
Via GlobeNewswire
News headline image
Dyadic Appoints Doug Pace to Its Executive Leadership Team
From Dyadic International, Inc.
Via GlobeNewswire
News headline image
Dyadic International Earnings Perspective: Return On Capital Employed ↗
 
Via Benzinga
News headline image
Earnings Outlook For Dyadic International ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Dyadic’s C1 Platform Selected by the Vaccine and Immunotherapy Center (“VIC”) at Massachusetts General Hospital as Part of VIC’s $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production of Prophylactic
From Dyadic International, Inc.
Via GlobeNewswire
News headline image
Dyadic to Present at Industry and Investor Events in October
From Dyadic International, Inc.
Via GlobeNewswire
News headline image
Dyadic and bYoRNA Announce a Collaboration Targeting the Production of Abundant, Low-Cost mRNA From C1-Cells
From Dyadic International, Inc.
Via GlobeNewswire
News headline image
Dyadic Announces Development and License Agreement to Commercialize Animal-Free Alternative Proteins Using Dapibus™
From Dyadic International, Inc.
Via GlobeNewswire
News headline image
Dyadic to Present at BioProcess International
From Dyadic International, Inc.
Via GlobeNewswire
News headline image
Dyadic Announces Continued Progress Towards Commercialization of Animal-Free Recombinant Serum Albumin
From Dyadic International, Inc.
Via GlobeNewswire
News headline image
Dyadic to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023
From Dyadic International, Inc.
Via GlobeNewswire
News headline image
Dyadic Provides Phase 1 Clinical Trial Update for its Recombinant Protein RBD Vaccine Candidate
From Dyadic International, Inc.
Via GlobeNewswire
News headline image
Dyadic Announced an MoU with Bangladesh’s State-Owned Pharmaceutical Company to Facilitate Biopharmaceutical Research and Biomanufacturing Capacity
From Dyadic International, Inc.
Via GlobeNewswire
News headline image
Dyadic to Participate at Upcoming Events in June
From Dyadic International, Inc.
Via GlobeNewswire
News headline image
Dyadic to Participate at Two Industry Events in May
From Dyadic International, Inc.
Via GlobeNewswire
News headline image
Dyadic Announces Collaboration to Commercialize Animal-Free Alternative Proteins Using Dapibus™
From Dyadic International, Inc.
Via GlobeNewswire
News headline image
Dyadic to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
From Dyadic International, Inc.
Via GlobeNewswire
News headline image
Dyadic Receives U.S. Patent for Manufacturing Seasonal and Pandemic Influenza Vaccines from its Proprietary C1 Protein Production Platform
From Dyadic International, Inc.
Via GlobeNewswire
News headline image
Dyadic Announces Expanded Licensing Agreement to Develop and Commercialize Vaccines and Biologics for African Continent
From Dyadic International, Inc.
Via GlobeNewswire
News headline image
Dyadic to Present at World Vaccine Congress Washington 2023
From Dyadic International, Inc.
Via GlobeNewswire
News headline image
Dyadic to Report 2022 Year End Financial Results on Wednesday, March 29, 2023
From Dyadic International, Inc.
Via GlobeNewswire
News headline image
Dyadic Provides Phase 1 Clinical Trial Update for its DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
From Dyadic International, Inc.
Via GlobeNewswire
News headline image
Dyadic to Present at Roth Investor Conference and Upcoming Industry Events
From Dyadic International, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Dyadic to Participate in Two Upcoming Investor Conferences
From Dyadic International, Inc.
Via GlobeNewswire
News headline image
Dyadic Announces Initiation of Dosing of First-In-Human Phase 1 Trial to Demonstrate Clinical Safety and Antibody Response in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
From Dyadic International, Inc.
Via GlobeNewswire
News headline image
Dyadic Announces Sale of Equity Interest in Alphazyme
From Dyadic International, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >